Clinical value of serum HMGB1 levels in early detection of recurrent squamous cell carcinoma of uterine cervix: Comparison with serum SCCA, CYFRA21-1, and CEA levels

Croatian Medical Journal

Volumn 50, Issue 5, 2009, Pages 455-464

  Sheng, Xiugui ^a   Du, Xuelian ^a   Zhang, Xiaoling ^a   Li, Dapeng ^a   Lu, Chunhua ^a   Li, Qinshui ^a   Ma, Zhifang ^a   Song, Quqing ^a   Wang, Cong ^a  

^a SHANDONG CANCER HOSPITAL AND INSTITUTE   (China)

Author keywords

[No Author keywords available]

Indexed keywords

CARCINOEMBRYONIC ANTIGEN; CYTOKERATIN 19 FRAGMENT; HIGH MOBILITY GROUP B1 PROTEIN; SQUAMOUS CELL CARCINOMA ANTIGEN;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; DIAGNOSTIC VALUE; EARLY DIAGNOSIS; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; PROTEIN BLOOD LEVEL; RECURRENT CANCER; SENSITIVITY AND SPECIFICITY; SQUAMOUS CELL CARCINOMA; UTERINE CERVIX CARCINOMA;

ADULT; AGED; AGED, 80 AND OVER; ANALYSIS OF VARIANCE; ANTIGENS, NEOPLASM; CARCINOEMBRYONIC ANTIGEN; CARCINOMA, SQUAMOUS CELL; CASE-CONTROL STUDIES; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HMGB1 PROTEIN; HUMANS; IMMUNOHISTOCHEMISTRY; KERATIN-19; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; ROC CURVE; SENSITIVITY AND SPECIFICITY; SERPINS; SURVIVAL ANALYSIS; TUMOR MARKERS, BIOLOGICAL; UTERINE CERVICAL NEOPLASMS;

EID: 72449193670     PISSN: 03539504     EISSN: 13328166     Source Type: Journal    
DOI: 10.3325/cmj.2009.50.455     Document Type: Article

References (37)

1. Parkin DM, Bray FI, Devesa SS. Cancer burden in the year 2000. The global picture. Eur J Cancer. 2001;37 Suppl 8:S4-66. Medline:11602373 doi:10.1016/S0959-8049(01)00267-2
2. Goldie SJ, Kuhn L, Denny L, Pollack A, Wright TC. Policy analysis of cervical cancer screening strategies in low-resource settings: clinical benefits and cost-effectiveness. JAMA. 2001;285:3107-15. Medline:11427139 doi:10.1001/jama.285.24.3107
3. Lai CH, Hong JH, Hsueh S, Ng KK, Chang TC, Tseng CJ, et al. Preoperative prognostic variables and the impact of postoperative adjuvant therapy on the outcomes of Stage IB or II cervical carcinoma patients with or without pelvic lymph node metastases: an analysis of 891 cases. Cancer. 1999;85:1537-46. Medline:10193944 doi:10.1002/(SICI)1097-0142(19990401)85:7<1537::AID- CNCR15>3.0.CO;2-6 (Pubitemid 29152826)
4. Waggoner SE. Cervical cancer. Lancet. 2003;361:2217-25. Medline:12842378 doi:10.1016/S0140-6736(03)13778-6 (Pubitemid 36782559)
5. Bodurka-Bevers D, Morris M, Eifel PJ, Levenback C, Bevers MW, Lucas KR, et al. Posttherapy surveillance of women with cervical cancer: an outcomes analysis. Gynecol Oncol. 2000;78:187-93. Medline:10926801 doi:10.1006/gyno.2000. 5860 (Pubitemid 30650352)
6. Maiman M. The clinical application of serum squamous cell carcinoma antigen level monitoring in invasive cervical carcinoma. Gynecol Oncol. 2002;84:4-6. Medline:11748968 doi:10.1006/ gyno.2001.6532
7. Gadducci A, Tana R, Cosio S, Genazzani AR. The serum assay of tumour markers in the prognostic evaluation, treatment monitoring and follow-up of patients with cervical cancer: a review of the literature. Crit Rev Oncol Hematol. 2008;66:10-20. Medline:17964182 doi:10.1016/j.critrevonc.2007.09.002 (Pubitemid 351324130)
8. Ferrandina G, Macchia G, Legge F, Deodato F, Forni F, Digesu C, et al. Squamous cell carcinoma antigen in patients with locally advanced cervical carcinoma undergoing preoperative radiochemotherapy: association with pathological response to treatment and clinical outcome. Oncology. 2008;74:42-9. Medline:18544959 doi:10.1159/000138979 (Pubitemid 351915009)
9. Tabata T, Takeshima N, Tanaka N, Hirai Y, Hasumi K. Clinical value of tumor markers for early detection of recurrence in patients with cervical adenocarcinoma and adenosquamous carcinoma. Tumour Biol. 2000;21:375-80. Medline:11006578 doi:10.1159/000030143
10. Brezniceanu ML, Volp K, Bosser S, Solbach C, Lichter P, Joos S, et al. HMGB1 inhibits cell death in yeast and mammalian cells and is abundantly expressed in human breast carcinoma. FASEB J. 2003;17:1295-7. Medline:12759333
11. Volp K, Brezniceanu ML, Bosser S, Brabletz T, Kirchner T, Gottel D, et al. Increased expression of high mobility group box 1 (HMGB1) is associated with an elevated level of the antiapoptotic c-IAP2 protein in human colon carcinomas. Gut. 2006;55:234-42. Medline:16118352 doi:10.1136/gut.2004.062729 (Pubitemid 43117284)
12. Kuniyasu H, Chihara Y, Kondo H, Ohmori H, Ukai R. Amphoterin induction in prostatic stromal cells by androgen deprivation is associated with metastatic prostate cancer. Oncol Rep. 2003;10:1863-8. Medline:14534709
13. Takada M, Hirata K, Ajiki T, Suzuki Y, Kuroda Y. Expression of receptor for advanced glycation end products (RAGE) and MMP-in human pancreatic cancer cells. Hepatogastroenterology. 2004;51:928-30. Medline:15239215
14. Cheng BQ, Jia CQ, Liu CT, Lu XF, Zhong N, Zhang ZL, et al. Serum high mobility group box chromosomal protein 1 is associated with clinicopathologic features in patients with hepatocellular carcinoma. Dig Liver Dis. 2008;40:446-52. Medline:18294942 doi:10.1016/j.dld.2007.11.024
15. Sasahira T, Akama Y, Fujii K, Kuniyasu H. Expression of receptor for advanced glycation end products and HMGB1/amphoterin in colorectal adenomas. Virchows Arch. 2005;446:411-5. Medline:15789216 doi:10.1007/s00428-005-1210-x (Pubitemid 40674848)
16. Pecorelli S, Odicino F. Cervical cancer staging. Cancer J. 2003;9:390-4. Medline:14690314 doi:10.1097/00130404-200309000-00009
17. Zou KH, O'Malley AJ, Mauri L. Receiver-operating characteristic analysis for evaluating diagnostic tests and predictive models. Circulation. 2007;115:654-7. Medline:17283280 doi:10.1161/ CIRCULATIONAHA .105.594929
18. Walter SD, Sinuff T. Studies reporting ROC curves of diagnostic and prediction data can be incorporated into meta-analyses using corresponding odds ratios. J Clin Epidemiol. 2007;60:530-4. Medline:17419965 doi:10.1016/j. jclinepi.2006.09.002 (Pubitemid 46529145)
19. Micke O, Prott FJ, Schafer U, Tangerding S, Potter R, Willich N. The impact of squamous cell carcinoma (SCC) antigen in the follow-up after radiotherapy in patients with cervical cancer. Anticancer Res. 2000;20:5113-5. Medline:11326679
20. Esajas MD, Duk JM, de Bruijn HW, Aalders JG, Willemse PH, Sluiter W, et al. Clinical value of routine serum squamous cell carcinoma antigen in follow-up of patients with early-stage cervical cancer. J Clin Oncol. 2001;19:3960-6. Medline:11579117
21. Chan YM, Ng TY, Ngan HY, Wong LC. Monitoring of serum squamous cell carcinoma antigen levels in invasive cervical cancer: is it cost-effective? Gynecol Oncol. 2002;84:7-11. Medline:11748969 doi:10.1006/gyno.2001.6497 (Pubitemid 34056459)
22. Gaarenstroom KN, Kenter GG, Bonfrer JM, Korse CM, Van de Vijver MJ, Fleuren GJ, et al. Can initial serum cyfra 21-1, SCC antigen, and TPA levels in squamous cell cervical cancer predict lymph node metastases or prognosis? Gynecol Oncol. 2000;77:164-70. Medline:10739706 doi:10.1006/gyno.2000.5732 (Pubitemid 30217320)
23. Chang TC, Law KS, Hong JH, Lai CH, Ng KK, Hsueh S, et al. Positron emission tomography for unexplained elevation of serum squamous cell carcinoma antigen levels during follow-up for patients with cervical malignancies: a phase II study. Cancer. 2004;101:164-71. Medline:15222002 doi:10.1002/cncr.20349 (Pubitemid 38812436)
24. Pras E, Willemse PH, Canrinus AA, de Bruijn HW, Sluiter WJ, ten Hoor KA, et al. Serum squamous cell carcinoma antigen and CYFRA 21-1 in cervical cancer treatment. Int J Radiat Oncol Biol Phys. 2002;52:23-32. Medline:11777619
25. Suzuki Y, Nakano T, Ohno T, Abe A, Morita S, Tsujii H. Serum CYFRA 21-1 in cervical cancer patients treated with radiation therapy. J Cancer Res Clin Oncol. 2000;126:332-6. Medline:10870643 doi:10.1007/s004320050352
26. Inal E, Lacin M, Asal K, Ceylan A, Koybasioglu A, Ileri F, et al. The significance of ferritin, lipid-associated sialic acid, CEA, squamous cell carcinoma (SCC) antigen, and CYFRA 21-1 levels in SCC of the head and neck. Kulak Burun Bogaz Ihtis Derg. 2004;12:23-30. Medline:16010093
27. Molina R, Filella X, Lejarcegui JA, Pahisa J, Torne A, Rovirosa A, et al. Prospective evaluation of squamous cell carcinoma and carcinoembryonic antigen as prognostic factors in patients with cervical cancer. Tumour Biol. 2003;24:156-64. Medline:14610320 doi:10.1159/000073846 (Pubitemid 37465053)
28. Molina R, Filella X, Auge JM, Bosch E, Torne A, Pahisa J, et al. CYFRA 21.1 in patients with cervical cancer: comparison with SCC and CEA. Anticancer Res. 2005;25:1765-71. Medline:16033097
29. Hao Q, Du XQ, Fu X, Tian J. Expression and clinical significance of HMGB1 and RAGE in cervical squamous cell carcinoma [in Chinese]. Zhonghua Zhong Liu Za Zhi. 2008;30:292-5. Medline:18788635
30. Gardella S, Andrei C, Ferrera D, Lotti LV, Torrisi MR, Bianchi ME, et al. The nuclear protein HMGB1 is secreted by monocytes via a non-classical, vesicle-mediated secretory pathway. EMBO Rep. 2002;3:995-1001. Medline:12231511 doi:10.1093/embo-reports/ kvf198
31. Kuniyasu H, Oue N, Wakikawa A, Shigeishi H, Matsutani N, Kuraoka K, et al. Expression of receptors for advanced glycation end-products (RAGE) is closely associated with the invasive and metastatic activity of gastric cancer. J Pathol. 2002;196:163-70. Medline:11793367 doi:10.1002/path.1031 (Pubitemid 34110897)
32. Maeda S, Hikiba Y, Shibata W, Ohmae T, Yanai A, Ogura K, et al. Essential roles of high-mobility group box 1 in the development of murine colitis and colitis-associated cancer. Biochem Biophys Res Commun. 2007;360:394-400. Medline:17599806 doi:10.1016/ j.bbrc.2007.06.065
33. Ellerman JE, Brown CK, de Vera M, Zeh HJ, Billiar T, Rubartelli A, et al. Masquerader: high mobility group box-1 and cancer. Clin Cancer Res. 2007;13:2836-48. Medline:17504981 doi:10.1158/1078-0432.CCR-06-1953 (Pubitemid 46850704)
34. Kuniyasu H, Chihara Y, Takahashi T. Co-expression of receptor for advanced glycation end products and the ligand amphoterin associates closely with metastasis of colorectal cancer. Oncol Rep. 2003;10:445-8. Medline:12579287
35. Dumitriu IE, Baruah P, Manfredi AA, Bianchi ME, Rovere-Querini P. HMGB1: guiding immunity from within. Trends Immunol. 2005;26:381-7. Medline:15978523 doi:10.1016/j.it.2005.04.009 (Pubitemid 40835844)
36. Evans A, Lennard TW, Davies BR. High-mobility group protein 1(Y): metastasis-associated or metastasis-inducing? J Surg Oncol. 2004;88:86-99. Medline:15499602 doi:10.1002/jso.20136 (Pubitemid 39536509)
37. Taguchi A, Blood DC, del Toro G, Canet A, Lee DC, Qu W, et al. Blockade of RAGE-amphoterin signalling suppresses tumour growth and metastases. Nature. 2000;405:354-60. Medline:10830965 doi:10.1038/35012626 (Pubitemid 30337069)